Introduction: Several randomized controlled trials (RCTs), conducted in schizophrenic and bipolar patients, have documented the efficacy and tolerability of asenapine as monotherapy both for short- and long-term treatment. However, evidence on its augmentative use is more limited and related to the manic/mixed phase of bipolar disorder (BD).Areas covered: The present article reviews augmentative asenapine efficacy and safety/tolerability in the treatment of BD. It also includes some original cases of bipolar patients treated with add-on asenapine in the short- and long-term.Expert opinion: To date, only a single RCT with manic/mixed patients with partial response to mood-stabilizer monotherapy supports the efficacy and safety/tolerability o...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Asenapine is mo...
BACKGROUND: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with w...
OBJECTIVE: Depression is the predominant psychosocial and suicide burden in bipolar disorder, yet th...
Introduction: Bipolar I disorder (BDI) is amongst the most debilitating psychiatric conditions with ...
Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comor...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-cont...
Jodi M Gonzalez1, Peter M Thompson1, Troy A Moore1,21University of Texas Health Science Center, San ...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-contr...
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks....
Maurizio Pompili1,2, Paola Venturini1, Marco Innamorati1, Gianluca Serafini1, Ludovica Telesforo1, D...
AbstractBackgroundAsenapine (ASN) is approved in the United States as monotherapy and adjunctive the...
Abstract INTRODUCTION: Asenapine is a sublingually administered second-generation antipsychotic ...
Background: Asenapine is a second-generation antipsychotic approved in Europe for treating moderate-...
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks....
Calvert G Warren,1 Steven L Dubovsky1,21Department of Psychiatry, State University of New York at Bu...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Asenapine is mo...
BACKGROUND: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with w...
OBJECTIVE: Depression is the predominant psychosocial and suicide burden in bipolar disorder, yet th...
Introduction: Bipolar I disorder (BDI) is amongst the most debilitating psychiatric conditions with ...
Bipolar disorder is a chronic mental illness associated with high levels of somatic morbidity, comor...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-cont...
Jodi M Gonzalez1, Peter M Thompson1, Troy A Moore1,21University of Texas Health Science Center, San ...
The aim of this study was to quantitatively review, using a meta-analytic approach, randomized-contr...
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks....
Maurizio Pompili1,2, Paola Venturini1, Marco Innamorati1, Gianluca Serafini1, Ludovica Telesforo1, D...
AbstractBackgroundAsenapine (ASN) is approved in the United States as monotherapy and adjunctive the...
Abstract INTRODUCTION: Asenapine is a sublingually administered second-generation antipsychotic ...
Background: Asenapine is a second-generation antipsychotic approved in Europe for treating moderate-...
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks....
Calvert G Warren,1 Steven L Dubovsky1,21Department of Psychiatry, State University of New York at Bu...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not Asenapine is mo...
BACKGROUND: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with w...
OBJECTIVE: Depression is the predominant psychosocial and suicide burden in bipolar disorder, yet th...